MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), today announces that its recent Phase II/III Alzheimer’s study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.Interested parties are encouraged to register for the upcoming investor call today at 4:30 PM ET, where detailed findings will be discussed.

宾夕法尼亚州马尔文，2024年6月11日（环球通讯社）--通过IBN-Annovis Bio Inc.（纽约证券交易所：ANVS）（“Annovis”或“该公司”），一家为阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病开发新疗法的晚期药物平台公司，今天宣布，其最近对其主要候选药物Buntanetap进行的II/III期阿尔茨海默病研究显示，载脂蛋白E4（APOE4）的携带者和非携带者在统计学上均具有显着的疗效和安全性。载脂蛋白E4是AD的遗传原因。鼓励感兴趣的各方在美国东部时间今天下午4:30注册即将到来的投资者电话会议，详细结果将公布已讨论。

https://zoom.us/webinar/register/3117176913600/WN_Ev_1s7l2RUKmIQJNdko5iAKey Findings:Scientific Context: Recent findings published in Nature Medicine have redefined APOE4 homozygosity as a distinct genetic form of Alzheimer’s disease, requiring individualized prevention strategies, clinical trials, and treatments.

https://zoom.us/webinar/register/3117176913600/WN_Ev_1s7l2RUKmIQJNdko5iAKey研究结果：科学背景：发表在《自然医学》上的最新发现将APOE4纯合性重新定义为阿尔茨海默病的一种独特遗传形式，需要个性化的预防策略，临床试验和治疗。

This study emphasized the near-full penetrance of AD biology in APOE4 homozygotes, suggesting that these patients represent a significant target group for therapeutic interventions.Safety Insights: Dr. Samuel Gandy, an Alzheimer’s researcher at Mount Sinai, highlighted the heightened safety risks for APOE4 homozygotes from anti-amyloid drugs, such as Leqembi, which have been associated with serious side effects like brain swelling and bleeding.

这项研究强调了APOE4纯合子中AD生物学的几乎完全外显，表明这些患者代表了治疗干预的重要目标人群。安全见解：西奈山阿尔茨海默氏病研究人员塞缪尔·甘迪博士强调了抗淀粉样蛋白药物（如Leqembi）对APOE4纯合子的安全风险增加，这些药物与脑肿胀和出血等严重副作用有关。

When the Food and Drug Administration approved the anti-amyloid drug Leqembi last year, it required a black-box warning — the agency’s strongest caution — because of safety concerns for people with two copies of APOE4. However, Buntanetap demonstrated no increased safety issues compared to placebo, even in APOE4 carriers.During our upcoming investor call, we will discuss the recent.

当食品和药物管理局去年批准抗淀粉样蛋白药物Leqembi时，它需要一个黑匣子警告-该机构最强烈的警告-因为对携带两份APOE4的人的安全问题。然而，即使在APOE4携带者中，与安慰剂相比，Buntanetap也没有显示出增加的安全性问题。在我们即将举行的投资者电话会议上，我们将讨论最近的情况。